Literature DB >> 11129495

Nonparametric rank-based methods for group sequential monitoring of paired censored survival data.

S Murray1.   

Abstract

This research gives methods for nonparametric sequential monitoring of paired censored survival data in the two-sample problem using paired weighted log-rank statistics with adjustments for dependence in survival and censoring outcomes. The joint asymptotic closed-form distribution of these sequentially monitored statistics has a dependent increments structure. Simulations validating operating characteristics of the proposed methods highlight power and size consequences of ignoring even mildly correlated data. A motivating example is presented via the Early Treatment Diabetic Retinopathy Study.

Entities:  

Mesh:

Year:  2000        PMID: 11129495     DOI: 10.1111/j.0006-341x.2000.0984.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  4 in total

1.  Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates.

Authors:  Pei-Fang Su; Chung-I Li; Yu Shyr
Journal:  Comput Stat Data Anal       Date:  2014-06-01       Impact factor: 1.681

2.  Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Susan Halabi
Journal:  Lifetime Data Anal       Date:  2019-04-12       Impact factor: 1.588

3.  Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients.

Authors:  Vibha N Lama; Susan Murray; Jeanette A Mumford; Kevin R Flaherty; Andrew Chang; Galen B Toews; Marc Peters-Golden; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

4.  Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival.

Authors:  Brian P Hobbs; Peter F Thall; Steven H Lin
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2015-10-26       Impact factor: 1.864

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.